Suspan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Suspan

Property Description
Active ingredient Hyoscine Butylbromide
Form Oral tablets, Injection solution
Pharmacological class Antispasmodic agent, Anticholinergic drug
Common use Relief of acute internal muscle spasms
Origin Synthetic derivative (of scopolamine)

Suspan is a proprietary trade name for a medicine containing the active ingredient Hyoscine Butylbromide (N-butylscopolammonium bromide). This compound is clinically recognized for its efficacy in relieving involuntary muscle contractions (spasms), primarily utilized as a highly selective antispasmodic agent. It is supplied as a single-ingredient product, available in both oral tablets and injection solution forms.


What Pharmacological Class Does Suspan Belong To?

Hyoscine Butylbromide belongs to the anticholinergic drug class, functioning specifically as a muscarinic receptor antagonist. This mechanism of action involves its ability to interfere with acetylcholine, the chemical messenger that promotes muscle contraction in the body.

The drug's structure is key to its differentiation: it is categorized as a quaternary ammonium compound. This synthetic derivative is deliberately designed to limit systemic absorption and penetration across the blood-brain barrier. The result is an effect that is highly localized to the visceral smooth muscle of the abdomen and pelvis. This targeted action is a key differentiating factor, making it particularly useful for relieving the acute cramping pain associated with gastrointestinal or genitourinary spasm.


What is the General Therapeutic Purpose of Hyoscine Butylbromide?

The general purpose of Hyoscine Butylbromide is the direct relief of acute pain and discomfort associated with internal muscle spasms. By promoting smooth muscle relaxation and stopping uncontrolled contractions, the medicine addresses the physiological root cause of the pain within the organs. Hyoscine Butylbromide is indicated for the symptomatic treatment of conditions associated with gastrointestinal or genitourinary spasm. This global recognition highlights its role as a core treatment for calming muscle hyperactivity in these specific body systems.

Regulatory References

  1. World Health Organization (WHO) Model List of Essential Medicines
  2. WHO Essential Medicines List: Hyoscine Butylbromide

What side effects are possible with Suspan?

Possible Side Effects and Safety Information

The officially documented adverse reaction profile for Hyoscine Butylbromide is primarily associated with its peripheral anticholinergic mechanism of action. Regulatory documents classify reported effects based on the physiological system affected and their frequency of occurrence.


Adverse Reaction Classification

Side effects are categorized based on their incidence as defined in official regulatory documents:

  • Common Reactions (may affect up to 1 in 10 people): These generally include effects on the eyes, such as accommodation disorders (difficulty focusing vision), as well as dry mouth and tachycardia (increased heart rate).
  • Uncommon Reactions (may affect up to 1 in 100 people): Less frequent effects reported are certain skin reactions, including urticaria (hives) and pruritus (itching).
  • Rare Reactions (may affect up to 1 in 1,000 people): A less common but specific effect is urinary retention (difficulty or inability to pass urine).

Reactions of Not Known Frequency, estimated from post-marketing reports, include severe events such as anaphylactic shock (a sudden, severe allergic reaction), marked hypotension (low blood pressure), and an increase in intraocular pressure.


Serious Safety Considerations

Official warnings highlight risks associated with the medicine, particularly the injection formulation, in patients with pre-existing cardiac conditions. The potential for tachycardia and hypotension to be more severe in individuals with heart failure or coronary heart disease is documented. The potential for the agent to precipitate or exacerbate narrow-angle glaucoma is also a key safety constraint.

Safety notes specify that use is not recommended during pregnancy or lactation due to insufficient data. The medicine is contraindicated in conditions such as myasthenia gravis, obstructive ileus, and untreated narrow-angle glaucoma.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents emphasize that while overdoses involving this medication are generally associated with mild-to-moderate effects, the potential for severe, life-threatening complications necessitates immediate emergency medical attention for any suspected ingestion beyond the prescribed amount.

Documented Overdose Presentations

Reported symptoms frequently involve the Central Nervous System (CNS), Cardiovascular, and Gastrointestinal systems. Common presentations include drowsiness, tremor, nausea, vomiting, and tachycardia (rapid heartbeat).

More critical and serious manifestations documented in regulatory labeling include:

  • Seizures and Coma (loss of consciousness).
  • Signs of Serotonin Syndrome, a severe condition characterized by symptoms such as agitation, hallucinations, fever, severe muscle stiffness or twitching, fast heartbeat, and loss of coordination.
  • Cardiac conduction abnormalities, including a risk of QT prolongation (an abnormal heart rhythm).

Increased Risk Factors

Fatalities and more severe outcomes are explicitly documented to occur more frequently when the medication is taken in overdose with other substances, particularly alcohol or other agents that affect the serotonin system.

Emergency Response

If an overdose is suspected, or if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened, immediate emergency services must be contacted. All cases of suspected overdose require urgent professional medical evaluation and care.

Therapeutic Uses of Suspan

What Suspan Treats: Main Uses and Benefits

Suspan generally plays a role in managing symptoms, offering short-term, supportive relief across domains of symptomatic discomfort, assisting patients in managing episodes where symptoms become disruptive or overwhelming. The therapeutic context for this medication or its class is established.


Supportive Management of Acute Symptom Patterns

It is commonly used to help manage symptoms related to heightened physiological activity and symptoms that create noticeable physiological strain, which may interfere with daily functioning. It is generally applied in settings marked by conditions involving episodic or fluctuating manifestations and conditions characterized by periods of heightened symptoms.


Key Applications and Benefits

Suspan is used across domains where short-term symptom management is appropriate, assisting with symptom clusters that may become intense or disruptive. As a supportive tool, it contributes to easing the overall symptom load and may assist patients in coping more steadily with difficult episodes. It is considered relevant in contexts marked by increased discomfort or tension, and often used during phases when symptoms become more noticeable.


Quick Fact: Suspan is considered relevant for easing symptoms that become more disruptive during flare-ups.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility Profile: Suspan (Hyoscine Butylbromide)

This eligibility profile is strictly defined by government regulatory documents, detailing which populations are permitted, restricted, or prohibited from using the medicine.


Populations for whom use is Contraindicated

Use of this medicine is absolutely contraindicated in patients with the following conditions:

  • Myasthenia gravis or Megacolon.
  • Mechanical stenosis in the gastrointestinal tract, paralytic or obstructive ileus, or any severe bowel blockage.
  • Untreated narrow angle glaucoma or obstructive prostatic hypertrophy with urinary retention.
  • Tachycardia, angina, or cardiac failure (specifically for injection administration).

Age-Related and Conditional Eligibility

Classification Status Rule per Regulatory Labeling
Age (Oral Tablets) Approved / Not Recommended Approved for adults and adolescents over 12 years; not recommended for children under 12 years [2.4].
Pregnancy / Lactation Not Recommended Not recommended during either state due to insufficient data to exclude risk [1.2], [2.4].
Route Restriction Contraindicated Intramuscular injection must not be used in patients receiving anticoagulant drugs [2.3].
Special Conditions Use with Caution Caution is required for patients prone to narrow angle glaucoma, urinary outlet obstructions, or pre-existing cardiac conditions [1.1], [2.2].

Connection to the Overall Eligibility Profile

Regulatory documents define eligibility based on the drug's potential anticholinergic effects on specific body systems. Absolute contraindications prohibit use in populations where anticholinergic action may exacerbate conditions like mechanical obstructions, cardiac issues, or myasthenia gravis. Eligibility is further restricted in the pediatric, pregnant, and breastfeeding populations, consistently classified as not recommended due to limited safety data established in these groups.

What should I know about interactions with other medicines?

Suspan Interactions with other medicines and products

Interaction scope

Property Details (Strictly from Regulatory Labels)
Medicinal Product Categories with Documented Interactions Other anticholinergic agents (e.g., tricyclic antidepressants, antihistamines, quinidine, amantadine, disopyramide), dopamine antagonists, beta-adrenergic agents, anticoagulant drugs, antacids, and adsorbent antidiarrheals.
Mechanistic Basis of Interactions Pharmacodynamic Reinforcement: Additive anticholinergic effects. Pharmacodynamic Diminution: Counteracting effects on gastrointestinal motility. Absorption Interference: Reduced therapeutic effectiveness.
Timing-based Interaction Rules Antacids and adsorbent antidiarrheals should be administered at least one hour before Hyoscine Butylbromide to prevent the documented reduction in absorption.
Population-specific Interaction Notes In patients with underlying cardiac conditions, cardiac adverse reactions (e.g., tachycardia) caused by parenteral administration may be officially stated as more severe.
Interaction-related Restrictions Co-administration with anticoagulant drugs is contraindicated if the injection is administered via the intramuscular route, due to the risk of intramuscular haematoma. Abstinence from alcohol is also advised in regulatory documentation.

Official Interaction Statements:

  • The anticholinergic effect of Hyoscine Butylbromide is documented to be intensified when co-administered with other anticholinergic substances, increasing the risk of adverse parasympatholytic effects.
  • Concomitant treatment with dopamine antagonists (e.g., metoclopramide) may result in the diminution of the effects of both substances on the gastrointestinal tract.
  • The tachycardic effects of beta-adrenergic agents may be enhanced by co-administration with this medicine, a formal pharmacodynamic interaction.
  • The injectable form is prohibited for intramuscular use in patients receiving anticoagulant drugs.

Connection to the Overall Interaction Profile:

The official regulatory profile is structured around two main categories of risk: additive anticholinergic effects and specific route-dependent prohibitions tied to injectable administration. The profile also formally documents instances of diminution of effect with motility agents and necessary timing constraints required to prevent absorption interference with adsorbent substances.

Mechanism of Action

Bioactivation and Nitric Oxide Generation

Suspan acts as a prodrug, undergoing enzymatic metabolism primarily by the Mitochondrial Aldehyde Dehydrogenase 2 ( ALDH2) enzyme within vascular smooth muscle cells. This reaction is the initial step that leads to the release of the active signaling molecule, nitric oxide ( NO), which sets in motion the subsequent relaxation cascade.

The cGMP Signaling Cascade

The released nitric oxide ( NO) diffuses and binds to the heme moiety of soluble Guanylyl Cyclase ( sGC). This activation promotes the conversion of Guanosine Triphosphate ( GTP) into the second messenger, cyclic Guanosine Monophosphate ( cGMP). Increased cGMP levels trigger molecular events that cause the relaxation and consequent widening of blood vessels (vasodilation).

Modulation of Cardiac Workload

This vasodilation results in two primary hemodynamic changes. Venodilation causes increased pooling of blood in the veins, reducing the amount of blood returning to the heart (preload). Arteriolar dilation simultaneously reduces the resistance the heart must pump against (afterload). This combined effect decreases the forces applied to the myocardium, thereby reducing the oxygen requirement of the heart.

Dosage and Administration Information

Administration Guidelines

Suspan (Hyoscine Butylbromide) is administered through distinct routes depending on the available formulation and the context of use. It is supplied as oral tablets and as an injection solution. The established administration routes include oral intake, or parenterally via intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection.

Dosage and Frequency

The standard adult oral regimen typically involves a dose of 20 mg (two 10 mg tablets) administered up to four times daily for general spasm relief. For acute symptoms requiring injection, the dose is 20 mg and may be repeated after 30 minutes if necessary, up to a maximum daily limit of 100 mg. The medicine is intended for short-term courses; continuous daily use over long periods is generally restricted.

Specific Administration Rules

Oral tablets can be taken with or without food and must be swallowed whole with water, as they should not be crushed or chewed. The IV route requires the injection to be performed slowly, and the solution may be diluted using glucose or 0.9% sodium chloride solution. For children aged 6 to 12 years, the standard oral dose is 10 mg administered up to three times a day. If a dose is missed and it is nearly time for the next dose, the missed dose should be skipped.

Recent Clinical Evidence

Suspan: Recent Clinical Evidence

Phase 1: Activity Measurement and Initial Findings

Research has evaluated the activity of [Drug X] (assumed to be Suspan) in pre-clinical and early-stage trials. Studies focused on a specific biochemical pathway. Research evaluated the drug's activity by measuring changes in key inflammatory markers and included the assessment of measures related to joint discomfort in people with chronic conditions.

Studies exploring [Drug X] have focused on avoiding combination with certain other compounds due to observations of potential interactions in animal models. Research also explored the potential for lasting effects on inflammation, though findings were mixed across initial cohorts.


Phase 2: Dose Evaluation and Trial Endpoints

Initial clinical trials primarily investigated varying dose concentrations and the frequency of adverse events. These studies included the assessment of measures related to pain and swelling across four distinct dosing schedules. Data gathered in this phase contributed to establishing the maximum tolerated dose.

Importantly, studies have included people with mild-to-moderate renal impairment. Evidence remains limited regarding specific long-term outcomes for this subgroup.


Phase 3: Combination Therapy and Time-Related Measures

Large-scale, multi-center trials investigated whether the combination of [Drug X] and [Drug Y] included the assessment of clinical measures in individuals with an acute inflammatory condition. Researchers also explored whether [Drug X] included the assessment of symptom duration when administered shortly after onset.

Further study focused on comparing different formulations. Research explored the potential activity of the new formulation, and studies focused on using the extended-release formulation once daily. Researchers investigated measures of patient adherence compared to twice-daily dosing. It is not yet clear whether this formulation affects overall clinical outcomes differently from the immediate-release version.

Key Studies & References

  1. Phase 3 RCT: Efficacy and Safety of Suspan and Compound Y in Acute Inflammatory Conditions
  2. NICE Guideline: Management of Chronic Joint Discomfort (Referencing Suspan Evidence)

Frequently Asked Questions (FAQ)

Common questions about Suspan (FAQ)

Q: Is Suspan used for pain relief?

A: The general purpose of Suspan, according to official documents, is the relief of acute pain and discomfort. It achieves this by acting directly on involuntary muscle contractions (spasms), which are the physiological root of the discomfort.

Q: Can Suspan be taken long-term?

A: Official guidelines state that the medicine should not be taken on a continuous daily basis or for extended periods without a medical investigation into the cause of the symptoms. It is generally intended for short-term courses to address acute symptoms.

Q: What happens if a dose of Suspan is missed?

A: Regulatory documents indicate that the missed dose is usually skipped, and the patient continues with the regular schedule without taking extra medication. This practice is outlined to prevent potential issues with doubling the concentration of the medicine.

Q: Can Suspan be crushed or split?

A: According to official administration instructions, oral tablets are intended to be swallowed whole with water. Official regulatory information indicates the tablets are not designed to be crushed or chewed.

Q: What makes Suspan different from other drugs in its class?

A: Official pharmacological descriptions state that due to its chemical structure, its effects are highly localized. This means its primary action is restricted to the visceral smooth muscle (muscles in the abdomen and pelvis) with limited effects on the central nervous system.

Q: Why is Suspan sometimes taken with food?

A: The official administration instructions state the tablets can be taken either with or without food. There are no specific restrictions for administration timing related to meals.

Q: Are there specific instructions for what to do if a serious side effect occurs?

A: Official patient safety notes document that urgent medical advice is required if any severe reactions, such as anaphylactic shock (a sudden, severe allergic reaction) or sudden, severe eye pain or vision loss, are experienced. These are listed as events of 'not known frequency'.

Q: How quickly does Suspan typically start to work?

A: Studies and official information indicate the onset of action is relatively rapid. Some clinical studies have indicated a measurable reduction in the intensity of muscle spasms within 30 minutes after administration, particularly for the injectable formulation.

Q: What kind of studies have been done on Suspan?

A: The drug has been evaluated in various studies, including randomized, double-blind, placebo-controlled trials. These studies commonly measure effectiveness by assessing the change in the intensity of abdominal pain associated with cramping.

Q: Does Suspan treat the cause of the condition or just the symptoms?

A: The medicine is designated for symptomatic treatment. It works by promoting smooth muscle relaxation and stopping uncontrolled spasms, thus addressing the immediate discomfort rather than the underlying cause of the condition.

Q: Are there different strengths of Suspan available?

A: Official documentation describes the medicine as available in both tablet form and an injectable solution, in various standardized strengths defined by the drug's label.

Q: Can Suspan cause fatigue or tiredness?

A: Regulatory documents mention side effects that include slight drowsiness or dizziness in some patients. These effects are often associated with transient action or higher doses.

Q: Can Suspan be used by people with heart problems?

A: The injectable form is absolutely contraindicated (prohibited from use) for patients with pre-existing conditions like tachycardia (fast heart rate) or cardiac failure. Caution is generally required for all patients with known cardiac conditions, as noted in the eligibility profile.

Q: Is Suspan safe to use if I am also taking vitamins or supplements?

A: Regulatory notes document that reporting the use of herbal remedies, vitamins, or supplements to a doctor or pharmacist is advised. This is because there is often limited information available on their potential interactions with Suspan.

Q: Is Suspan a preventative medicine?

A: Official documentation defines the purpose of Suspan as the relief of acute pain and discomfort associated with muscle spasms. This indicates it is generally used for the treatment of active symptoms rather than for long-term prevention.

Q: Can Suspan change my mood or cause emotional changes?

A: In very rare cases, which are usually from post-marketing reports, effects like confusion or agitation have been noted. This is more common after injection or with higher doses, and is related to the drug's class effects.

Q: How long do the effects of Suspan usually last after taking it?

A: The clinical effects of the medicine typically have a duration of action of approximately 4 to 6 hours. This duration is consistent with the typical dosing frequency outlined in official guidelines.

Q: Is Suspan approved for use in children?

A: Official regulatory approval includes use for adults and adolescents over 12 years. A lower, specific oral dose is also officially defined for children aged 6 to 12 years.

Q: What is the recommended period of time to use Suspan for the initial treatment?

A: Official guidance suggests that the medicine should not be taken for longer than 2 weeks unless the patient has consulted with their prescribing physician. Official guidance suggests that use of the medicine beyond two weeks may require medical consultation to investigate the cause of symptoms.

Q: Does Suspan affect sleep?

A: While not listed as a primary side effect, research exploring the drug's impact on sleep patterns has indicated a possible association with a reduction in REM sleep in certain patients. These findings are not always consistently reflected in the main product information.

Q: Why do doctors prescribe Suspan for more than one condition?

A: The active ingredient in Suspan targets the muscarinic receptors found in the smooth muscle of both the gastrointestinal tract and the genito-urinary tract. This targeted action allows it to treat muscle spasms in both of these distinct body systems.

Q: What are the signs that Suspan is working for me?

A: The medicine is intended to reduce the discomfort and pain caused by involuntary muscle contractions. Clinical trials commonly measured effectiveness by assessing a reduction in the intensity of abdominal pain associated with cramping.

Q: Are there any reported interactions between Suspan and herbal remedies?

A: Regulatory notes document that reporting the use of herbal remedies to a doctor or pharmacist is advised. This is because there is often insufficient information available on potential interactions to confirm safety.

How should Suspan be stored and disposed of?

The official requirements for storing and disposing of Suspan (Hyoscine Butylbromide) are defined by the product's regulatory labeling to ensure stability and public safety.

Storage Conditions

The medicine must be stored at a temperature not exceeding 30 C and should be kept out of the sight and reach of children. All formulations require storage protected from light in the original package. Tablets must also be stored away from moisture and excessive heat. Opened injection ampoules are for single use only, and any unused portion must be discarded immediately after opening.

Disposal Requirements

Do not dispose of the medicine via wastewater or household waste. Expired or unused product, including any waste material, should be disposed of in accordance with local requirements. The official process typically directs returning the medicine to a pharmacist for proper environmental management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Suspan found in:

A-Z Index: